LMP-420

• Description :

  LMP-420 is a selective tumor necrosis factor-α (TNF-α) inhibitor. LMP-420 reduces the release of pro-inflammatory cytokines (e.g., IL-1β, IL-2), inducing the expression of anti-inflammatory cytokine IL-10 and anti-apoptotic molecules SOCS-1 and Mn-SOD. LMP-420 also downregulates chemokines (e.g., IP-10, MCP-1) to reduce immune cell infiltration. LMP-420 is promising for research of type 1 diabetes mellitus, inflammatory diseases (e.g., colitis), and HIV-Mycobacterium tuberculosis coinfection[1].

• UNSPSC :

  12352005

• Hazard Statement :

  H302-H315-H319-H335

• Target :

  Interleukin Related; TNF Receptor

• Related Pathways :

  Apoptosis; Immunology/Inflammation

• Field of Research :

  Infection; Metabolic Disease; Inflammation/Immunology

• Smiles :

  ClC1=C2N=CN(CCCCCB(O)O)C2=NC(N)=N1

• Molecular Formula :

  C10H15BClN5O2

• Molecular Weight :

  283.52

• Precautions :

  P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501

• References & Citations :

  [1]Angaswamy N, et al. LMP-420, a small molecular inhibitor of TNF-α, prolongs islet allograft survival by induction of suppressor of cytokine signaling-1: synergistic effect with cyclosporin-A. Cell Transplant. 2012;21 (6) :1285-96.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound2

• Clinical Information :

  No Development Reported

• CAS Number :

  [473870-63-2]